Interaction of histone H1 with cis-platinum modified DNA.
Cis-diamminedichloroplatinum(II) (cis-DDP) is known as an effective anticancer drug. Its therapeutic effect is supposed to be a consequence of the covalent binding to DNA. A number of cellular proteins were found to bind selectively to DNA modified by cis-DDP (but not by its isomer trans-DDP). Here we present our observations on interaction of the linker histone H1 with cis- and trans-DDP modified DNA fragments. The results afford new experimental information about the preferential binding of histone H1 to cis-DDP-distorted DNAs versus trans-DDP modified ones.
Paneva
E G
EG
Institute of Molecular Biology, Bulgarian Academy of Sciences, Sofia, Bulgaria.
Spassovska
N C
NC
Grancharov
K C
KC
Zlatanova
J S
JS
Yaneva
J N
JN
D002945:Cisplatin / Q000378:metabolism*; D018736:DNA Adducts / Q000378:metabolism*; D006609:High Mobility Group Proteins / Q000378:metabolism; D006657:Histones / Q000378:metabolism*; D006801:Humans
D018736:DNA Adducts; D006609:High Mobility Group Proteins; D006657:Histones; C057270:cisplatin-DNA adduct; D002945:Cisplatin